MEDiCS project at BIOSPAIN

October 17, 2025

The MEDICS project made it to BIOSPAIN 2025 !

Last week, at Asphalion’s booth in BIOSPAIN, our team of experts shared insights on the MEDiCS project, a Horizon Europe-funded initiative tackling two critical cancer challenges: therapy resistance in colorectal cancer (CRC) and poor prognosis in pancreatic ductal adenocarcinoma (PDAC).

MEDiCS aims to advance the TRL from 3-4 to 5 through scalable manufacturing processes, GLP in-vivo studies, and the creation of a spin-out for commercialization. Asphalion is leading the regulatory roadmap, ensuring all study results are captured in the IMPD by the end of the project.

It was inspiring to discuss the project and its potential impact with visitors and showcase how innovation, research, and regulatory strategy come together to advance cancer therapy.

For more information, contact us at [email protected]

Search News & Events

  • Filter by category

Share

Related news and events

HORIZON | SPIOMET4HEALTH Final Policy Event

The SPIOMET4HEALTH Final Policy Event brought together researchers, clinicians, patient representatives and policymakers to discuss the future of Polyendocrine Metabolic Ovarian Syndrome (#PMOS) and the

HORIZON | SPIOMET4HEALTH Final Project Meeting

The SPIOMET4HEALTH Final Project Meeting is currently taking place in Bologna, Italy, marking an important milestone after four years of research into Polyendocrine Metabolic Ovarian

siNPAIN | Project closure

Four and a half years of research, collaboration and innovation to advance the future of osteoarthritis treatment.

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting